TABLE 2.
In vitro activity of carbapenems and comparator antimicrobial agents against P. aeruginosa isolates from ICUs (2017 to 2018)
| Specimen source or susceptibility and antimicrobial agent | Susceptibility status (%) |
MIC determination (μg/ml) |
||||
|---|---|---|---|---|---|---|
| Susceptible | Intermediate | Resistant | MIC50 | MIC90 | MIC range | |
| Respiratory tract (n = 433) | ||||||
| Ceftazidime | 74.6 | 4.1 | 21.3 | 4 | 64 | 0.125 to >64 |
| Ceftazidime-avibactam | 91.7 | —a | 8.3 | 2 | 8 | 0.125 to >64 |
| Imipenem | 63.3 | 5.3 | 31.4 | 2 | 32 | 0.125 to >64 |
| Imipenem-relebactam | 90.1 | 6.5 | 3.4 | 0.25 | 2 | 0.03 to >32 |
| Meropenem | 69.1 | 5.5 | 25.4 | 1 | 16 | 0.06 to >64 |
| Bloodstream (n = 104) | ||||||
| Ceftazidime | 87.5 | 5.8 | 6.7 | 2 | 64 | 0.5 to 64 |
| Ceftazidime-avibactam | 97.1 | — | 2.9 | 2 | 8 | 0.5 to 32 |
| Imipenem | 82.7 | 4.8 | 12.5 | 2 | 16 | 0.25 to >64 |
| Imipenem-relebactam | 97.1 | 1.9 | 1 | 0.25 | 1 | 0.125 to >32 |
| Meropenem | 87.5 | 1.9 | 10.6 | 0.5 | 8 | 0.06 to >64 |
| Carbapenem-NS (n = 189) | ||||||
| Ceftazidime | 58.2 | 8.5 | 33.3 | 8 | 64 | 0.5 to >64 |
| Ceftazidime-avibactam | 84.7 | — | 15.3 | 4 | 16 | 0.5 to >64 |
| Imipenem | 6.4 | 14.8 | 78.8 | 16 | 32 | 1 to >64 |
| Imipenem-relebactam | 75.7 | 15.9 | 8.4 | 1 | 4 | 0.06 to >32 |
| Meropenem | 22.2 | 13.8 | 64 | 8 | 32 | 0.125 to >64 |
| Ceftazidime-NS (n = 123) | ||||||
| Ceftazidime | 0 | 19.5 | 80.5 | 64 | 128 | 16 to >64 |
| Ceftazidime-avibactam | 71.5 | — | 28.5 | 8 | 32 | 1 to >64 |
| Imipenem | 40.6 | 4.9 | 54.5 | 8 | 32 | 0.5 to >64 |
| Imipenem-relebactam | 77.3 | 14.6 | 8.1 | 1 | 4 | 0.125 to >32 |
| Meropenem | 41.5 | 5.6 | 52.9 | 8 | 32 | 0.06 to >64 |
a
—, CLSI intermediate breakpoint currently not available.